LYRA
Lyra Therapeutics, Inc.Company Information
- Company Name
- Lyra Therapeutics, Inc.
- CIK
- CIK0001327273
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- LYRA: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 3841
- SIC Description
- Surgical & Medical Instruments & Apparatus
- Ticker
- LYRA
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-11-10
- Last sale
- 2026-01-06
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 55,032
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 104,059
- Shares outstanding
- 1,553,473
- Ownership
- 6.70%
Earnings Market Reaction
- Filing date
- 2026-03-31
- Price on filing date
- —
- 1-month reaction
- 44.69%
- 3-month reaction
- 38.46%
Balance Sheet
Values in millions ($)| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 16 | 22 | 30 | 32 | 41 | 24 | 32 | 16 | 22 | 25 | 54 | 22 | ||||||
| Prepaid Expense And Other Assets Current | 0 | 1 | 1 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Short Term Investments | 0 | - | - | - | 0 | 28 | 36 | 71 | 80 | 78 | 62 | 61 | ||||||
| Restricted Cash Current | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Assets Current | 16 | 23 | 31 | 34 | 43 | 54 | 69 | 89 | 105 | 105 | 118 | 85 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | 2 | 1 | 1 | 2 | ||||||
| Operating Lease Right Of Use Asset | 17 | 18 | 18 | 19 | 20 | 21 | 21 | 46 | 33 | 6 | 1 | 2 | ||||||
| Restricted Cash Noncurrent | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | ||||||
| Assets | 36 | 44 | 53 | 56 | 66 | 79 | 95 | 142 | 143 | 121 | 126 | 94 | ||||||
Liabilities Current | ||||||||||||||||||
| Other Assets Noncurrent | - | - | - | - | 0 | - | - | 1 | 1 | 7 | 4 | 4 | ||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 3 | 3 | 5 | 4 | 4 | ||||||
| Restructuring Reserve Current | 3 | 3 | 3 | 4 | 4 | 5 | 3 | - | - | - | - | - | ||||||
| Accrued Liabilities And Other Liabilities | 1 | - | - | - | 3 | - | - | - | 9 | - | - | - | ||||||
| Operating Lease Liability Current | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 5 | 5 | 1 | 2 | 2 | ||||||
| Deferred Revenue Current | - | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 1 | 2 | ||||||
| Liabilities Current | 10 | 9 | 11 | 11 | 13 | 15 | 19 | 19 | 20 | 19 | 14 | 14 | ||||||
| Operating Lease Liability Noncurrent | 25 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 21 | 5 | - | 0 | ||||||
| Deferred Revenue Noncurrent | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | ||||||
| Liabilities | 47 | 48 | 51 | 52 | 55 | 58 | 64 | 64 | 53 | 36 | 27 | 28 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 423 | 422 | 422 | 417 | 416 | 414 | 413 | 411 | 401 | 380 | 379 | 331 | ||||||
| Retained Earnings Accumulated Deficit | -434 | -427 | -421 | -413 | -405 | -394 | -382 | -334 | -311 | -296 | -281 | -265 | ||||||
| Stockholders Equity | -11 | -4 | 2 | 4 | 12 | 21 | 31 | 78 | 89 | 84 | 99 | 66 | ||||||
| Liabilities And Stockholders Equity | 36 | 44 | 53 | 56 | 66 | 79 | 95 | 142 | 143 | 121 | 126 | 94 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | - | 0 | 0 | -0 | 0 | 0 | -0 | -0 | -0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialLyra Therapeutics, Inc. (LYRA) — SEC Financial Statements & Analysis
Lyra Therapeutics, Inc. (LYRA) is a surgical & medical instruments & apparatus company, incorporated in DE. Lyra Therapeutics, Inc. trades on OTC as: LYRA. Lyra Therapeutics, Inc. (LYRA)'s most recent SEC filing is a Form 10-K for the period ended 2025-12-31, filed with the SEC on 2026-03-31. Based on its latest SEC filing (Form 10-Q, period ending 2025-12-31), Lyra Therapeutics, Inc. carries a market cap of $4.78M, a P/E ratio of -0.17x, a P/B ratio of -0.45x, a P/S ratio of 12.02x, an enterprise value of $-11.11M, and an EV/EBITDA multiple of 0.36x. On profitability, it posts an operating margin of -7794.47%, a net margin of -7266.08%, a Return on Equity (ROE) of -6594.98%, a Return on Assets (ROA) of -56.45%, and a Return on Invested Capital (ROIC) of -138.46%. Per share, it reports EPS of $-18.62, diluted EPS of $-18.62, free cash flow per share of $-18.65, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -74.05% year-over-year, net income growth of -69.05% year-over-year, and EPS growth of -74.05% year-over-year. On the balance sheet, it maintains a current ratio of 1.71x, a quick ratio of 1.67x, working capital of $6.75M, a debt-to-equity ratio of -4.37x, a debt ratio of 1.3, free cash flow of $-28.98M (TTM), and net debt of $-15.89M. Figures sourced from SEC EDGAR.
- Market Cap
- $4.78M
- P/E TTM
- -0.17x
- EPS TTM
- $-18.62
- P/B TTM
- -0.45x
- ROE TTM
- -6594.98%
- ROA TTM
- -56.45%
- Debt To Equity
- -4.37x
- Free Cash Flow TTM
- $-28.98M
- Net Revenue TTM Growth 1Y
- -74.05%
Data as of 2025-12-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Lyra Therapeutics, Inc. in?
Lyra Therapeutics, Inc. (LYRA) operates in the Surgical & Medical Instruments & Apparatus industry.
What exchange does LYRA trade on?
Lyra Therapeutics, Inc. (LYRA) trades on the OTC.
Where is Lyra Therapeutics, Inc. incorporated?
Lyra Therapeutics, Inc. is incorporated in DE.
When was Lyra Therapeutics, Inc. (LYRA)'s most recent SEC filing?
Lyra Therapeutics, Inc. (LYRA)'s most recent SEC filing is a Form 10-K for the period ended 2025-12-31, filed with the SEC on 2026-03-31.
What is LYRA's market cap?
Lyra Therapeutics, Inc. (LYRA) has a market capitalization of $4.78M as of 2025-12-31.
What is LYRA's EPS (earnings per share)?
Lyra Therapeutics, Inc. (LYRA)'s trailing twelve month EPS is $-18.62 as of 2025-12-31.
What is LYRA's ROE (return on equity)?
Lyra Therapeutics, Inc. (LYRA)'s trailing twelve month Return on Equity (ROE) is -6594.98% as of 2025-12-31.
What is LYRA's ROA (return on assets)?
Lyra Therapeutics, Inc. (LYRA)'s trailing twelve month Return on Assets (ROA) is -56.45% as of 2025-12-31.
What is LYRA's ROIC (return on invested capital)?
Lyra Therapeutics, Inc. (LYRA)'s trailing twelve month Return on Invested Capital (ROIC) is -138.46% as of 2024-03-31.
What is LYRA's EV/EBITDA?
Lyra Therapeutics, Inc. (LYRA)'s trailing twelve month EV/EBITDA is 0.36x as of 2025-12-31.